Meadow's mailing address filed with the SEC is C/O BOYU CAPITAL ADVISORY CO. LIMITED,, SUITE 1518, TWO PACIFIC PL, 88 QUEENSWAY, HONG KONG, , .
Over the last 5 years, insiders at Viela Bio have traded over 58,712,400$ worth of Viela Bio stock and bought 1,261,091 units worth 24,062,867$ . The most active insiders traders include Andreas Wicki、Xiaomeng Tong、Plc Astra Zeneca Uk Ltd Ast.... On average, Viela Bio executives and independent directors trade stock every 41 days with the average trade being worth of 6,348$. The most recent stock trade was executed by Aaron Ren on 18 November 2020, trading 2,000 units of VIE stock currently worth 5,680$.
Viela Bio, Inc., a clinical-stage biotechnology company, engages in the research and development of treatments for severe inflammation and autoimmune diseases in the United States. The company's lead product candidate is inebilizumab, a humanized monoclonal antibody for neuromyelitis optica spectrum disorder, kidney transplant desensitization, myasthenia gravis, and IgG4-related diseases. It is also developing VIB4920 for kidney transplantation rejection and sjögren's syndrome; and VIB7734 for cutaneous lupus erythematosus. Viela Bio, Inc. has a strategic collaboration with Mitsubishi Tanabe Pharma Corporation to develop and commercialize inebilizumab for autoimmune diseases in Japan, Thailand, South Korea, Indonesia, Vietnam, Malaysia, the Philippines, Singapore, and Taiwan. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Viela Bio executives and other stock owners filed with the SEC include: